

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/023,933	12/21/2001	Marc Nazare	02481.1768	7773
7590 02/25/2004			EXAMINER	
Finnegan, Henderson, Farabow,			KUMAR, SHAILENDRA	
Garrett & Dunner, L.L.P.			ADTIBUT	DADED MUMBED
1300 I Street, N.W.			ART UNIT	PAPER NUMBER
Washington, DC 20005-3315			1621	

DATE MAILED: 02/25/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

10	1
'V~	12

	Application No.	Applicant(s)			
	10/023,933	NAZARE ET AL.			
Office Action Summary	Examiner	Art Unit			
	SHAILENDRA - KUMAR	1621			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	rely filed  s will be considered timely. the mailing date of this communication.  O (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on <u>02 De</u>	ecember 2003.				
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This	☐ This action is <b>FINAL</b> . 2b) ☐ This action is non-final.				
3) Since this application is in condition for allowar					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	i3 O.G. 213.			
Disposition of Claims					
4) ⊠ Claim(s) 1-21 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-21 are subject to restriction and/or expressions.	vn from consideration.				
Application Papers					
9)☐ The specification is objected to by the Examine 10)☐ The drawing(s) filed on is/are: a)☐ acce		Examiner.			
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correcting 11) The oath or declaration is objected to by the Ex					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign  a) All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the prior  application from the International Bureau  * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been receive n (PCT Rule 17.2(a)).	on No d in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary Paper No(s)/Mail Da				
Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)     Paper No(s)/Mail Date		atent Application (PTO-152)			

- 1. This office action is in response to applicants' communication filed on 12/2/03.
- 2. The restriction requirement of paper no. 8 mailed on 9/26/03, is hereby vacated, and a new restriction requirement is made as follows:
- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claim 1-9, 11-21, drawn to compounds, composition, method of making and method of use, when compounds are totally non heterocyclic, classified in class various, subclass various.
  - II. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is aziridine, classified in class various, subclass various.
  - III. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is oxirane, classified in class various, subclass various.
  - IV. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is azetidine, classified in class various, subclass various.
  - V. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyrrole, classified in class various, subclass various.

- VI. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is furan or thiophene, classified in class various, subclass various.
- VII. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is dioxole, classified in class various, subclass various.
- VIII. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is imidazole classified in class various, subclass various.
- IX. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyrazole, classified in class various, subclass various.
- X. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is oxazole, classified in class various, subclass various.
- XI. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is isoxazole, classified in class various, subclass various.
- XII. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is thiazole or isothiazole, classified in class various, subclass various.

- XIII. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is 1,2,3, triazole or 1,2,4 triazole classified in class various, subclass various.
- IVX. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is tetrazole, classified in class various, subclass various.
- VX. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyridine, classified in class various, subclass various.
- VXI. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyran, or thiopyran, classified in class various, subclass various.
- VXII. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyradizine, classified in class various, subclass various.
- VXIII. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyrimidine, classified in class various, subclass various.
- 19. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyrazine classified in class various, subclass various.

- 20. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is oxaxines or thiazines, classified in class various, subclass various.
- 21. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is triazines, classified in class various, subclass various.
- 22. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is azepines and diazepines, classified in class various, subclass various.
- 23. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is indoles and isoindoles, classified in class various, subclass various.
- 24. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is benzofuran and benzothiophene, classified in class various, subclass various.
- 25. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is benzodioxole, classified in class various, subclass various.
- 26. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is indazole, classified in class various, subclass various.

- 27. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is chromane, classified in class various, subclass various.
- 28. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is benzimidazole, classified in class various, subclass various.
- 29. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is benzoxazole, classified in class various, subclass various.
- 30. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is benzothiazole, classified in class various, subclass various.
- 31. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is quinoline and isoquuinoline, classified in class various, subclass various.
- 32. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is cinnoline, classified in class various, subclass various.
- 33. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is quinazoline and quinoxaline, classified in class various, subclass various.

Art Unit: 1621

- 34. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is phthalazine, classified in class various, subclass various.
- 35. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pteridine, classified in class various, subclass various.
- 36. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyridopyridines, classified in class various, subclass various.
- 37. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyridoimidazoles, classified in class various, subclass various.
- 38. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is pyridopyrimidines, classified in class various, subclass various.
- 39. Claims 1-21, drawn to compounds, composition and method of making and method of treating, when any of R0, M, or any other substituent is purine, classified in class various, subclass various.

The inventions are distinct, each from the other because of the following reasons:

The above 1-39 groups are divergent chemical groups classified in various groups according to US classification system. There are numerous class/subclass for the above groups and hence were not classified. Once the election is done, the elected group will

Art Unit: 1621

be classified. The 39 groups are also distinct for the reasons that a reference anticipating one of the above groups may not render the others obvious under 35 USC 103.

Additionally, applicants need to elect a single disclose species for the either of the group elected for the examination purposes.

3. In view of the complexity of the restriction requirement, a written restriction requirement is hereby made...

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected 4. invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAILENDRA - KUMAR whose telephone number is (571)272-0640. The examiner can normally be reached on Mon-Thur 8:00-5:30, Alt Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571)272-0646. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1621

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SHAILENDRA - KUMAR Primary Examiner Art Unit 1621

S.Kumar 2/20/04